Antibody Clinical Trials

74 recruitingLast updated: June 17, 2026

There are 74 actively recruiting antibody clinical trials across 36 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Shanghai, China, Toulouse, France, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Antibody Trials at a Glance

74 actively recruiting trials for antibody are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 18 trials, with the heaviest enrollment activity in Shanghai, Toulouse, and Beijing. Lead sponsors running antibody studies include China Immunotech (Beijing) Biotechnology Co., Ltd., Sun Yat-sen University, and Tongji Hospital.

Treatments under study

About Antibody Clinical Trials

Looking for clinical trials for Antibody? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Antibody trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Antibody clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 74 trials

Recruiting
Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Amgen300 enrolled79 locationsNCT06072482
Recruiting
Phase 2

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

EGFR Activating MutationLung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody
Nanfang Hospital, Southern Medical University32 enrolled1 locationNCT07637448
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Nkarta, Inc.240 enrolled17 locationsNCT06733935
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled21 locationsNCT06308978
Recruiting
Phase 1Phase 2

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Marcela V. Maus, M.D.,Ph.D.12 enrolled1 locationNCT07388277
Recruiting

Frequency of SPAD in Adult Patients

Predominantly Antibody DeficienciesSpecific antibody deficiency
University Hospital, Lille99 enrolled1 locationNCT05664035
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 2

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease

Autoimmune EncephalitisAnti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
Arialys Australia Pty Ltd30 enrolled1 locationNCT07093333
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Hoffmann-La Roche152 enrolled82 locationsNCT05271409
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Phase 1

Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

Diffuse Alveolar HemorrhageAntineutrophil Cytoplasmic Antibody Positive Vasculitis
Mayo Clinic6 enrolled1 locationNCT07556484
Recruiting
Phase 2

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Kidney TransplantationAMRAntibody-mediated Rejection+1 more
Alexion Pharmaceuticals, Inc.45 enrolled55 locationsNCT06744647
Recruiting
Phase 3

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatosis With Polyangiitis
Assistance Publique - Hôpitaux de Paris42 enrolled1 locationNCT04871191
Recruiting
Phase 2

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Antibody-mediated Rejection
argenx30 enrolled23 locationsNCT06503731
Recruiting

Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity

Antibody Mediated Rejection After Kidney Transplantation
Assistance Publique - Hôpitaux de Paris45 enrolled2 locationsNCT07134491
Recruiting
Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Antibody-mediated Rejection
Biogen120 enrolled59 locationsNCT06685757
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519